Abstract
Mycobacterium tuberculosis continues to kill about 3 million people every year1, more than any other single infectious agent. This is attributed primarily to an inadequate immune response towards infecting bacteria, which suffer growth inhibition rather than death and subsequently multiply catastrophically. Although the bacillus Calmette–Guérin (BCG) vaccine is widely used, it has major limitations as a preventative measure2. In addition, effective treatment requires that patients take large doses of antibacterial drug combinations for at least 6 months after diagnosis3, which is difficult to achieve in many parts of the world and is further restricted by the emergence of multidrug-resistant strains of M. tuberculosis. In these circumstances, immunotherapy to boost the efficiency of the immune system in infected patients could be a valuable adjunct to antibacterial chemotherapy4. Here we show in mice that DNA vaccines, initially designed to prevent infection, can also have a pronounced therapeutic action. In heavily infected mice, DNA vaccinations can switch the immune response from one that is relatively inefficient and gives bacterial stasis to one that kills bacteria. Application of such immunotherapy in conjunction with conventional chemotherapeutic antibacterial drugs might result in faster or more certain cure of the disease in humans.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kochi, A. Global challenge of tuberculosis. Lancet 44, 608–609 (1994).
Bloom, B. R. & Fine, P. E. M. in Tuberculosis: Pathogenesis, Protection, and Control (ed. Bloom, B. R.) 531–557 (American Society for Microbiology, Washington DC, (1994).
Hong Kong Chest Service & British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Tubercle 63, 89–98 (1982).
Young, D. B. & Duncan, K. Prospects for new interventions in the treatment and prevention of mycobacterial disease. Annu. Rev. Microbiol. 49, 641–673 (1995).
Tascon, R. E. et al. Vaccination against tuberculosis by DNA injection. Nature Med. 2, 888–892 (1996).
Huygen, K. et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med. 2, 893–898 (1996).
Zhu, X. J. et al. Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis infection. J. Immunol. 158, 5921–5926 (1997).
Bonato, V. L. D., Lima, V. M. F., Tascon, R. E., Lowrie, D. B. & Silva, C. L. Identification and characterization of protective T cells in hsp65 DNA vaccinated and Mycobacterium tuberculosis infected mice. Infect. Immun. 66, 169–175 (1998).
Stenger, S. et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282, 121–125 (1998).
Altare, F. et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280, 1432–1435 (1998).
Donnelly, J. J., Ulmer, J. B., Shiver, J. W. & Liu, M. A. DNA vaccines. Annu. Rev. Immunol. 15, 617–648 (1997).
Orme, I. M., Roberts, A. D., Griffin, J. P. & Abrams, J. S. Cytokine secretion by CD4 T-lymphocytes acquired in response to Mycobacterium tuberculosis infection. J. Immunol. 15, 518–525 (1993).
Zhang, M. et al. T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect. Immun. 63, 3231–3234 (1995).
Krieg, A. M., LoveHoman, L., Yi, A. K. & Harty, J. T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocyto genes challenge. J. Immunol. 161, 2428–2434 (1998).
Lai, W. C., Pakes, S. P., Ren, K., Lu, Y. S. & Bennett, M. Therapeutic effect of DNA immunization of genetically susceptible mice infected with virulent Mycoplasma pulmonis. J. Immunol. 158, 2513–2516 (1997).
Johnston, S. A. & Barry, M. A. Genetic to genomic vaccination. Vaccine 15, 808–809 (1997).
Lowrie, D. B., Silva, C. L., Colston, M. J., Ragno, S. & Tascon, R. E. Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 15, 834–838 (1997).
Matsumoto, S. et al. Cloning and sequencing of a unique antigen MPT70 from Mycobacterium tuberculosis H37Rv and expression in BCG using E-coli Mycobacteria shuttle vector. Scand. J. Immunol. 41, 281–287 (1995).
Hewinson, R. G., Michell, S. L., Russell, W. P., McAdam, R. A. & Jacobs, W. R. Molecular characterization of MPT73: a seroreactive antigen of Mycobacterium tuberculosis with homology to MPT70. Scand. J. Immunol. 43, 490–499 (1996).
Trinchieri, G. Immunobiology of interleukin-12. Immunol. Res. 17, 269–278 (1998).
Flynn, J. L. et al. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J.Immunol. 155, 2515–2524 (1995).
Cooper, A. M., Magram, J., Ferrante, J. & Orme, I. M. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J. Exp. Med. 186, 39–45 (1997).
deJong, R. et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280, 1435–1438 (1998).
Mitchison, D. A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66, 219–225 (1985).
McCune, R. M., Feldmann, F. M., Lambert, H. P. & McDermott, W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123, 445–468 (1966).
Wiegeshaus, E., Balasubramanian, V. & Smith, D. W. Immunity to tuberculosis from the perspective of pathogenesis. Infect. Immun. 57, 3671–3676 (1989).
Smith, P. G. & Moss, A. R. in Tuberculosis: Pathogenesis, Protection, and Control (ed. Bloom, B. R.) 47–59 (American Society for Microbiology, Washington DC, (1994).
Tascon, R. E. et al. in Vaccine Design: The Role of Cytokine Networks (eds Gregoriadis, G., McCormack, B. & Allison, A. C.) 181–185 (Plenum, New York, (1997).
Chapman, B. S., Thayer, R. M., Vincent, K. A. & Haigwood, N. L. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res. 19, 3979–3986 (1991).
Schultz, J., Pavlovic, J., Strack, B., Nawrath, M. & Moelling, K. Long-lasting anti-metastatic efficiency of IL-12-encoding plasmid DNA. Hum. Gene Ther. (in the press).
Acknowledgements
This study was supported in part by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Financiadora de Estudos e Projetos (FINEP) and World Health Organization (WHO) Global Programme for Vaccination and Immunization.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lowrie, D., Tascon, R., Bonato, V. et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 400, 269–271 (1999). https://doi.org/10.1038/22326
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/22326
This article is cited by
-
The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development
Molecular Biomedicine (2022)
-
Immunogenicity and therapeutic effects of a Mycobacterium tuberculosis rv2190c DNA vaccine in mice
BMC Immunology (2017)
-
Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis
Scientific Reports (2017)
-
New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro
BMC Biotechnology (2016)
-
The Viability and Protein Expression of Beijing/W Lineage Mycobacterium tuberculosis Circulating in Xinjiang, China
Current Microbiology (2015)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.